Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer. It targets TRAIL-R1, also...
9 KB (751 words) - 21:40, 20 December 2023
develop antibody therapeutics. This deal generated belimumab, raxibacumab, mapatumumab and lexatumumab. In April 2012, the first three of these products formed...
12 KB (1,135 words) - 19:34, 18 June 2025
targets of several anti-cancer therapeutics since the mid-1990s, such as Mapatumumab. However, as of 2013, these have not shown significant survival benefit...
11 KB (1,335 words) - 03:21, 2 June 2025
hexanitrate (INN) mannomustine (INN) mannosulfan (INN) manozodil (INN) Maolate mapatumumab (INN) mapinastine (INN) mapracorat (INN) maprotiline (INN) maraciclatide...
4 KB (270 words) - 04:44, 24 November 2024
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
5 KB (305 words) - 05:22, 23 October 2024
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
49 KB (6,227 words) - 17:23, 29 April 2025
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
8 KB (316 words) - 13:53, 10 September 2024
Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus) Mapatumumab mab human TRAIL-R1 cancer Margetuximab Margenza mab humanized HER2 Y...
146 KB (4,464 words) - 06:26, 24 June 2025
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
9 KB (610 words) - 13:48, 14 January 2025
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
12 KB (1,387 words) - 20:47, 20 June 2025
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
24 KB (2,773 words) - 16:57, 11 June 2025
Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Linvoseltamab Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab# (+hyaluronidase, +relatlimab)...
5 KB (368 words) - 15:29, 21 August 2024
risk-benefit profile of raxibacumab". Two anti-TRAIL receptor antibodies – mapatumumab (HGS-ETR1) and lexatumumab (HGS-ETR2). Early work by CAT and HGS scientists...
92 KB (8,529 words) - 20:14, 29 May 2025
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
12 KB (1,464 words) - 12:49, 28 May 2025
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
20 KB (2,146 words) - 16:24, 21 August 2024
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
12 KB (1,460 words) - 07:49, 21 June 2025
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
12 KB (1,508 words) - 17:56, 19 August 2022
Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Linvoseltamab Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab# (+hyaluronidase, +relatlimab)...
4 KB (241 words) - 13:42, 14 July 2024
Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Linvoseltamab Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab# (+hyaluronidase, +relatlimab)...
3 KB (129 words) - 17:07, 28 May 2025